Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy With GC/GP Regimens for Non-small-cell Lung Carcinoma Using Recombinant Human Thrombopoietin (rhTPO)
This is a randomized, controlled, open-labeled, multicenter clinical trial. The subjects are
patients with NSCLC who are going to receive GC/GP regimen chemotherapy.
Vadhan-Raj et al conducted a study in which they administered rhTPO in various ways to
patients with sarcoma receiving platinum-containing chemotherapy. The results demonstrated
that timing of administration of rhTPO can be adjusted according to the occurrence time of
nadir platelet values induced by chemotherapy. The timing of administration of rhTPO in this
study was determined based on the above proofs.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
minimum and maximum value of platelet count after chemotherapy
To evaluate the minimum and maximum value of platelet count after chemotherapy and the value of platelet count and their D-values comparing with the baseline values
Yi-Long Wu, Professor
Guangdong General Hospital
China: Food and Drug Administration